Celtaxsys, a clinical-stage pharmaceutical development company, has indicated clinically meaningful improvements in pulmonary exacerbations in the phase two Empire- cystic fibrosis trial of Acebilustat, it was reported on Friday.
Acebilustat is a small molecule inhibitor of Leukotriene A4 Hydrolase, the crucial enzyme in the production of the potent inflammatory mediator Leukotriene B4. It has decreased the frequency of pulmonary exacerbations and increased the time to next exacerbation over 48 weeks of therapy in the 200-patient, double-blind and placebo controlled study.
Acebilustat-treated patients demonstrated 19% decrease in pulmonary exacerbations and 22% reduced risk in progressing to first pulmonary exacerbations against placebo, on a per protocol assessment. The once-daily oral drug candidate is advancing to phase three development. It was designed to modulate the neutrophil driven immune response and bring the inflammation to homeostasis, allowing to avoid overactive inflammation.
Sionna Therapeutics doses first healthy subject in SION-109 phase one clinical trial
Arcturus Therapeutics granted FDA Orphan Drug Designation for ARCT-032 to treat cystic fibrosis
SpliSense completes SPL84 first-in-human, Phase one clinical trial for cystic fibrosis treatment
Positive Phase 2, Proof-of-Concept Results for VX-548 Published in New England Journal of Medicine
Inogen acquires Physio-Assist, expanding respiratory product portfolio and global presence
cystetic Medicines doses first healthy volunteer in CM001 Phase one clinical trial